MedMira Inc. (TSXV:MIR)

Canada flag Canada · Delayed Price · Currency is CAD
0.0700
-0.0050 (-6.67%)
Jul 23, 2025, 11:38 AM EDT
-6.67%
Market Cap52.63M
Revenue (ttm)254.30K
Net Income (ttm)-4.66M
Shares Out701.73M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume323,453
Average Volume32,502
Open0.0750
Previous Close0.0750
Day's Range0.0700 - 0.0750
52-Week Range0.0700 - 0.1400
Beta0.56
RSI45.82
Earnings DateJun 27, 2025

About MedMira

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screenin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 52
Stock Exchange TSX Venture Exchange
Ticker Symbol MIR
Full Company Profile

Financial Performance

In 2024, MedMira's revenue was 412,568, a decrease of -4.61% compared to the previous year's 432,529. Losses were -3.33 million, 24.3% more than in 2023.

Financial Statements

News

MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada

HALIFAX, NS / ACCESS Newswire / July 7, 2025 / MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate M...

16 days ago - Accesswire

MedMira Reports Second Quarter Results FY2025

HALIFAX, NS / ACCESS Newswire / June 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q3 FY2025, MedMir...

22 days ago - Accesswire

MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense

HALIFAX, NS / ACCESS Newswire / April 17, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as ...

3 months ago - Accesswire

Medmira reports Q2 results

4 months ago - Seeking Alpha

MedMira Reports Second Quarter Results FY2025

HALIFAX, NS / ACCESS Newswire / April 1, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q2 FY2025, MedMir...

4 months ago - Accesswire

MedMira Announces Partnership with MediGroup Physician Services in the United States

HALIFAX, NS / ACCESS Newswire / February 27, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new partn...

5 months ago - Accesswire

MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada

HALIFAX, NS / ACCESS Newswire / February 25, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership ...

5 months ago - Accesswire

MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications

HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clin...

6 months ago - Accesswire

MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications

MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its...

6 months ago - Accesswire

MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use

HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal®...

6 months ago - Accesswire

MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use

MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Re...

6 months ago - Accesswire

MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trial...

6 months ago - Accesswire

MedMira Reports First Quarter Results FY2025

HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, Med...

7 months ago - Accesswire

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rap...

7 months ago - Accesswire

MedMira Reports FY2024 Fourth Quarter and Year End Financial Results

HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023,...

8 months ago - Accesswire

MedMira Announces the appointment of Vice President of Commercial Operations

MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as Vic...

10 months ago - Accesswire

MedMira Reports Third Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / July 2, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2024. Corporate update In Q3 FY2024, MedMira focuse...

1 year ago - Accesswire

MedMira Announces the Hire of Vice President of Business Development

HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of ...

1 year ago - Accesswire

MedMira Reports Second Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira...

1 year ago - Accesswire

MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test s...

1 year ago - Accesswire

CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products

Correction: Extended clarification. HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canad...

1 year ago - Accesswire

Corporate Update on Clinical Evaluation of MedMira's Products

HALIFAX, NS / ACCESSWIRE / February 1, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the required sub...

1 year ago - Accesswire

MedMira Reports First Quarter Results FY2024

HALIFAX, NS / ACCESSWIRE / December 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2023. Corporate update During Q1 FY2024, Med...

1 year ago - Accesswire

U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test

HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. (MedMira) (TSXV:MIR) proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Ra...

1 year ago - Accesswire

MedMira Reports FY2023 Fourth Quarter and Year End Financial Results

HALIFAX, NS / ACCESSWIRE / November 28, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2023. Corporate Update Throughout the re...

1 year ago - Accesswire